NCT02623296View on ClinicalTrials.gov

A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Healthy
Interventions
DRUG

GLPG1205

Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13

DRUG

Placebo

Once daily administration of 2 matching placebo capsules from Day 1 to Day 13

DRUG

Cocktail of CYP450 substrates

Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution

Trial Locations (1)

Unknown

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY